All News

Results presented at the 2019 NCPA Annual Convention

Governor Pritzker pushing for lighter pharmacy workloads.

Common collaborations include allergy, antibiotic, and opiate consultations.

Commercial launch suspended due to manufacturer liquidity.

What execs and experts think of the future of drug costs.

Fifth company warned about unsubstantiated claims this year.

New formulation improves safety for patients.

Approved in May 2019, granted to FoldRx, a subsidiary of Pfizer.

Previously approved for IV infusion.

What to expect for these high-dollar drugs.

Drug able to treat 18,000 people will cost over $300k per year.

Drug shortages might be decreasing, but their continued existence is urging the pharmacy industry to maintain its vigilance.

A look at incidence rates, survival rates, and more.

Available for prescribing starting January 2020

First approved in 2018 for patients 12 years of age and older.

Education can help pharmacists feel more comfortable dispensing care.

Originally approved in 1995 for use in adults only.

Job growth may stagnate and retail jobs continue to dwindle. 

Results of multi-generational study indicates risk reduction potential.

Study shows that efficacy is a major concern.

What new laws could mean for pharmacies’ role in combatting HIV.

Many cite PBM fees as the primary cause in NCPA survey.

The deal is now official, but the companies have been acting as one for some time.

Where pharmacists should be looking to live.

Administered via a once-daily transdermal patch.

Mothers and babies need the influenza and whooping cough vaccines, CDC says.

New and old non-opioid pain management solutions. 

Currently under DEA review.